Specifically, we evaluated the effects of lumican on various types of breast cancer cells; one positive for ERα (MCF-7, low invasive) and another positive for the ERβ (MDA-MB-231, highly invasive) before and after knockdown of these ERs, respectively. The gene discussed is ESR2; the disease is breast cancer.